Kodiak Sciences Q2 net loss widens to $55.9M; KSI-301 trials on track for data in early 2022

Kodiak Sciences Inc.

2022-Q2 EPS reported -$2.06

Net loss of $55.9M ($1.08/share) vs $26.0M ($0.58) in Q2 2020; R&D expenses rose to $45.4M.
Cash and equivalents $880.9M; royalty financing from BBA capped at $450M after second $125M tranche not paid.
Phase 3 wet AMD DAZZLE study on track topline data Q1 2022; enrollment in BEACON, GLEAM, GLIMMER, DAYLIGHT ongoing.
China IND approved for KSI-301 in RVO and DME; first patients expected in 2021.
Proposed INN for KSI-301 is tarcocimab tedromer; GLOW study in non-proliferative DR to start August 2021.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.